Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Name: Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Published: 2026
License: Public Domain

Blue Earth Diagnostics · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

prostate-cancer

prostate cancer, biochemical recurrence (bcr), positron emission tomography (pet) scan, negative or equivocal psma pet scan, interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Related documents